-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$1.50-64.2% Downside
Elicio Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Elicio Therapeutics, Inc.?
Elicio Therapeutics, Inc. has been rated by research analysts at Stifel Nicolaus in the past 90 days.